Upload Avatar (500 x 500)
Guo Ma
mg0328@126.com
Chinese, English
Shanghai
Fudan University
Pharmaceutical Sciences
  • 2004-2007 PhD in Pharmaceutics: West China School of Pharmacy, Sichuan University
  • 2001-2004 MSc in Pharmaceutics: Sichuan Antibiotics Industrial Institute, National Medical Products Administration
  • 1992-1996 BSc in Pharmacy: Shandong Medical University
  • 2024-present - Fudan University School of Pharmacy - Professor, Doctoral Supervisor, and Master's Supervisor
  • 2014-2023 - Fudan University School of Pharmacy - Associate Professor, Master's Supervisor, and Doctoral Supervisor
  • 2010-2011 - University of Houston College of Pharmacy - Visiting Scholar
  • 2007-2014 - Fudan University School of Pharmacy - Lecturer
  • 1996-2001 - Xiashan Hospital, Taian, Shandong - Pharmacist
  • 2023: Hong Kong Love Teaching Award
  • 2023: Fudan University Course Ideological and Political Benchmark Course
  • 2023: Excellent Mentor Award, China Pharmaceutical Industry Science and Technology Exchange Center
  • 2022: Shanghai Course Ideological and Political Demonstration Course
  • 2022: Shanghai Course Ideological and Political Demonstration Team
  • 2022: Fudan University Top Ten Teacher Team - Clinical Pharmacy Innovative Teaching Team
  • 2022: Shanghai Excellent Teaching Achievement Award First Prize
  • 2022: Fudan University Textbook Construction Award First Prize
  • 2020: One Health Fund Excellent Teacher Third Prize
  • 2018: Chinese Medical Association Medical Education Research Project First Prize
Research on the mechanism and pharmacodynamic material basis of traditional Chinese medicine (hypoglycemic) based on AI, network pharmacology, PK/PD, and multi-omics integration
ADME/Tox of Chinese and Western medicines and their regulation
Drug interactions mediated by nuclear receptors, transporters, and metabolic enzymes
Comprehensive clinical evaluation of drugs based on AI, evidence-based pharmacy, and real-world evidence
  • Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis, Yanan Ding, Yufei Shi, Ruifang Guan, Shiwei Yan, Haiyang Liu, Zihan Wang, Jiyifan Li, Tiandian Wang, Weimin Cai, Guo Ma, 2023
  • Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling, Ruifang Guan, Xuening Li, Guo Ma, 2023
  • Cardiovascular Benefits and Safety of Sotagliflozin in Type 2 Diabetes Mellitus Patients with Heart Failure or Cardiovascular Risk Factors: A Bayesian Network Meta-Analysis, Jiyifan Li, Chenyang Zhu, Jingru Liang, Jiarong Hu, Haiyang Liu, Zihan Wang, Ruifang Guan, Junwei Chow, Shiwei Yan, Longzhou Li, Fuyan Ma, Guo Ma, 2023
  • Efficacy and Safety of Teneligliptin in Patients with Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis, Miao Zhu, Ruifang Guan, Guo Ma, 2023
  • Effect of Astragali Radix Extract on Pharmacokinetic Behavior of Dapagliflozin in Healthy and Type 2 Diabetic Rat, Wandi Du, Jiarong Hu, Jingru Liang, Xiaolei Yang, Boyu Fan, Guo Ma, 2023
Ai Network Pharmacology Pk/Pd Multi-Omics Traditional Chinese Medicine Hypoglycemic Mechanism Pharmacodynamic Material Basis Research

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.